Bonding Health Introduces Emotional Regulation Score™ – The First Clinical-Grade Tool to Help ADHD Adults and Parents Measure and Build Emotional Mastery
The Emotional Regulation Score™ (ERS), was developed using the Emotion Regulation Questionnaire (ERQ) which is a well-accepted gold standard in psychological science developed by Gross & John (2003). The ERS brings decades of research into an actionable, mobile-first app experience created exclusively for ADHD brains.
'Emotional regulation has generally been treated as an abstract skill,' said Pen King Jr., CEO of Bonding Health. 'Now with the Emotional Regulation Score™ we are changing the game. For the first time ever, ADHD adults and parents have a way to measure this critically important ability, develop the skill through structured supports, and follow their progress over time, as we do with trackers for physical health.'
Addressing a Critical Need in ADHD Support
Emotional regulation is one of the most substantial predictors of long-term well-being (just the mind, but the body and relationships). It has ramifications for mental clarity, physical wellness and the quality of relationships both personally and professionally. In order to make improvements in emotional regulation, it is essential to measure it, however there are few specific individuals are able to measure emotional regulation (specifically individuals with ADHD), and furthermore few practices to develop it.
Bonding Health's Emotional Regulation Score™ provides a simple, data-driven mechanism to build self-awareness and emotional resilience.
Key Features of the Emotional Regulation Score™
Expanding Support Through PKJ Coaching
Bonding Health has teamed up with PKJ Coaching, a recognized leader in coaching programs focused on ADHD, to enhance user support. This partnership allows all users to not only learn from their Emotional Regulation Score™ but also receive personalized strategies and accountability to practice these skills in everyday life.
Availability
The Emotional Regulation Score™ will launch on Friday, July 25, 2025, with Version 4 of the Bonding Health app, available for both iOS and Android.
Download now to be first in line:
About Bonding Health
Bonding Health is a digital health company that supports individuals and families affected by ADHD to achieve a higher degree of emotional balance and resilience. Importantly, Bonding Health offers clinician-designed tools, daily habit trackers, and collective resources such as PKJ Coaching that continue to provide evidence-based resources that allow individuals to thrive rather than focus on medication.
Media Contact:
Pen King Jr.
CEO, Bonding Health
[email protected]
Media Contact
Company Name: Bonding Health
Contact Person: Pen King Jr.
Email: Send Email
State: New York
Country: United States
Website: http://www.bondinghealth.com
Source: AIO Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the 'Investor Relations' section of the Establishment Labs website at About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO 13485:2016 and FDA 21 CFR 820. Please visit our website for additional information at
Business Upturn
38 minutes ago
- Business Upturn
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
EMA's CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its dialogue with the EMA to explore a potential path forward to make Elevidys available to individuals living with DMD in the EU Roche believes the benefit-risk remains positive in the ambulatory Duchenne population Elevidys is the first and only disease-modifying gene therapy for DMD Basel, 25 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys™ (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD). Given the high unmet need in DMD, Roche plans to continue to work with the EMA to explore a potential path forward. 'We are disappointed by the CHMP's negative opinion, given the urgent need for disease-modifying therapies for children in the EU living with Duchenne,' said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development, Roche. 'With an average life expectancy of only 28 years, achieving disease stabilisation is a major advance for individuals living with Duchenne, their families and caregivers. We are confident in the value Elevidys can bring to ambulatory patients.' The CHMP opinion is based on data from the largest and broadest gene therapy clinical programme in DMD to date, including results from the pivotal Phase III EMBARK study that showed treatment with Elevidys provided sustained stabilisation or slowing of disease progression, and a consistent and manageable safety profile in ambulatory patients. To date, more than 900 individuals with DMD, 760 of whom are ambulatory, have been treated with Elevidys in clinical and real-world settings. While the primary endpoint was not met in EMBARK after one year, Elevidys showed clinically meaningful and statistically significant improvements across important secondary endpoints of functional outcome measures when compared to placebo. Longer term efficacy data were also submitted to EMA, including two-year results from the EMBARK study and three-year pooled efficacy analysis from three other Elevidys studies that showed clinically meaningful improvements across key measures of motor function. One-year data from part one of the EMBARK study were published in Nature Medicine in October 2024 and results from year two were shared at this year's Muscular Dystrophy Association clinical & scientific conference in Dallas, TX. DMD is a rare, genetic, muscle-wasting disease that progresses rapidly from early childhood. Everyone with Duchenne will eventually lose the ability to walk, along with upper limb, lung, and cardiac function. Average life expectancy is only 28 years. The physical, emotional, and financial impact of Duchenne on those affected, their families, and caregivers, is profound. Roche recognises there is a significant unmet medical need for those living with Duchenne and the urgency for treating children before DMD progresses to provide the best possible chance for improved outcomes. We are actively working with health authorities across the globe to bring Elevidys to patients and their families as soon as possible. Elevidys is the first and only approved gene therapy targeting the underlying cause of disease that consistently demonstrates stabilisation or slowing of DMD disease progression, with durable effects on functional and biological outcomes and muscle health. About Duchenne muscular dystrophy DMD primarily affects males, with 1 in 5,000 boys born worldwide having Duchenne. Everyone with Duchenne will eventually lose the ability to walk, along with upper limb, lung and cardiac function. Average life expectancy is only 28 years. The physical, emotional and financial impact of Duchenne on those affected, their families and caregivers, is profound. Duchenne is an X-linked, rare neuromuscular disease caused by pathogenic variants (mutations) in the DMD gene that disrupt the production of functional dystrophin protein, leading to progressive and irreversible muscle weakness, diminished quality of life and premature death. Dystrophin strengthens and protects muscles and without it, normal activity causes excessive damage to muscle cells as they are more sensitive to injury. Over time, muscle tissue is replaced with scar tissue and fat, causing muscles to weaken. Although Duchenne progresses differently in each individual, its devastating trajectory is well established. Those with Duchenne will eventually lose the ability to use and move their limbs, to breathe on their own and are susceptible to respiratory infections. Muscle damage to the heart causes cardiomyopathy, including rhythm abnormalities and heart failure. Early diagnosis is important for timely intervention to prolong muscle function and preserve quality of life. There is a critical need for disease-modifying treatments that address the underlying cause of DMD before irreversible muscle loss occurs. About Elevidys™ (delandistrogene moxeparvovec) Elevidys™ (delandistrogene moxeparvovec, also known as SRP-9001) is the first approved disease-modifying gene therapy for Duchenne and is designed to address the underlying cause of Duchenne through targeted skeletal, respiratory and cardiac muscle expression of shortened dystrophin produced by Elevidys. Elevidys is a one-time treatment administered through a single intravenous dose. Elevidys is contraindicated in individuals with any deletion in exons 8 and/or 9 in the DMD gene. Elevidys has been studied in the largest and broadest gene therapy clinical development program in DMD with the longest follow-up (up to six years) in patients of all ages, and with various DMD mutations. To date, more than 900 individuals with DMD (more than 760 of whom are ambulatory) have been treated with Elevidys across clinical and real-world settings and Elevidys is now approved in nine countries, including Japan. Important Elevidys Updates: On 15 June, Roche announced new dosing restrictions for Elevidys for non-ambulatory DMD patients, irrespective of age, in both clinical and commercial settings. These measures followed two reported fatalities in the non-ambulatory DMD population. On 22 July, in response to the U.S. Food and Drug Administration (FDA)'s request to Sarepta, Roche took additional measures towards initiating a voluntary and temporary pause of any new orders of Elevidys to countries outside the U.S. that reference the FDA as the basis for their local approval, and in Named Patient Supply (NPS) countries. Discussions with other relevant health authorities are ongoing. Roche will immediately respect requests to halt new orders and shipments from health authorities. Patient safety is Roche's highest priority. Based on the totality of available data, Roche believes that the benefit-risk profile is positive in the ambulatory patient population. To date, approximately 760 ambulatory DMD patients have been treated with Elevidys in clinical and real-world settings and there have been no treatment-related fatalities. Elevidys is being developed by Roche in collaboration with Sarepta Therapeutics About Roche in Neuroscience Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Investor Relations North America Loren KalmPhone: +1 650 225 3217 e-mail: [email protected] Attachment Media Investor Release Elevidys CHMP Opinion English Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Associated Press
3 hours ago
- Associated Press
PKJ Coaching Launches Groundbreaking Dopamine Recovery Program to Help ADHD Adults Taper Off Stimulants Without Losing Their Edge
Miami Beach, FL - July 25, 2025 - In a bold step away from conventional ADHD treatment models, Pen King Jr. — a former elite ski racer turned ADHD recovery coach — has launched PKJ Coaching, a revolutionary platform designed to help adults taper off prescription stimulants such as Adderall and Vyvanse while reclaiming their focus, energy, and emotional clarity — all without medication. With stimulant prescriptions and over-the-counter dopamine enhancers like nicotine pouches, caffeine, and SSRIs at an all-time high, many high-functioning adults are facing a hidden crisis: burnout, emotional numbness, and growing dependency on external chemicals for basic mental performance. PKJ Coaching aims to offer a radical new path — helping adults reset their nervous systems and rebuild dopamine naturally through neuroscience-backed coaching and personalized habit design. 'We've normalized dependency. People are taught that they can't function without a pill, a pouch, or a prescription,' says Pen King Jr., founder of PKJ Coaching. 'But the truth is, we can retrain the brain. We can rebuild dopamine resilience. That's what this program is all about.' A Personal Mission That Sparked a Movement After spending 17 years on prescription stimulants for ADHD, King experienced the same crash that many high performers face in silence — emotional burnout, loss of motivation, and a growing inability to function without medication. 'There came a point where I wasn't sure who I was without the pills,' says King. 'So I made a choice: quit cold turkey and start rebuilding. I spent years learning what the brain truly needs to regulate itself — and then I turned it into a method that others can use.' That method is now available through PKJ Coaching, a dopamine-first, drug-free coaching platform helping adults recover motivation, emotional clarity, and natural focus — without relying on medication. What Makes PKJ Coaching Different? Unlike general productivity or mindset coaching programs, PKJ Coaching is specifically designed for adults tapering off Adderall, Vyvanse, Zyn, SSRIs, and other common dopamine-altering substances. Key Features Include: 'This isn't just about productivity. It's about rewiring your entire nervous system to function without needing an external fix,' explains King. 'We're not anti-medication — we're anti-dependency.' Why the Anti-Adderall Era is Gaining Traction The rise in adult ADHD diagnoses, coupled with social trends around microdosing and stimulant use, has led to what King calls a 'dopamine dysregulation epidemic.' While ADHD is a real and serious condition, many adults are misdiagnosed or overmedicated, only to find themselves stuck in a perform-crash cycle: productive during the day but emotionally hollow at night. PKJ Coaching challenges this dynamic by offering an alternative to long-term stimulant use — one that helps clients achieve clarity, motivation, and emotional stability naturally. 'We're helping people wake up motivated and go to sleep peaceful — without pills. That's the future of ADHD care,' says King. Who PKJ Coaching is Built For PKJ Coaching is tailored for high-functioning adults who are seeking a smarter, sustainable way to manage their focus and energy without depending on medications. The program is ideal for: Whether you're a startup founder juggling too many tabs, an artist feeling creatively stuck, or a parent looking to break free from prescription dependency — PKJ Coaching offers a guided path toward mental resilience and renewed identity. Free Strategy Session Now Available Prospective clients can now book a free 1-on-1 strategy session with Pen King Jr., to evaluate their goals, current use of medication and their state of readiness to begin a structured tapering and recovery protocol. Visit to learn more or to book a consultation. About PKJ Coaching PKJ Coaching is a dopamine-first coaching platform founded by ADHD recovery coach Pen King Jr. The program combines stimulant tapering protocols, neuro-habit rewiring, and emotional regulation tools to help adults rebuild motivation and focus naturally — without relying on prescription drugs. Built for creatives, leaders, parents, and professionals, PKJ Coaching provides a personalized, science-backed path to mental clarity and resilience. Media Contact: Pen King Jr. Founder, PKJ Coaching [email protected] Media Contact Company Name: PKJ Coaching Contact Person: Pen King Jr. Email: Send Email City: Miami Beach State: Florida Country: United States Website: Source: AIO Newswire
